FDA approves Merck’s Idvynso for suppressed HIV-1 adults
Bottom line
Merck said the US FDA approved Idvynso, a once-daily, two-drug tablet combining doravirine and islatravir, on April 21, 2026, for adults with HIV-1 who are already virologically suppressed and switching from a stable antiretroviral regimen. The label is narrow: it applies to adults with HIV-1 RNA below 50 copies/mL, no history of virologic treatment failure, and no known doravirine-resistance substitutions. Merck framed the approval as a treatment-simplification option, and the company said the regimen is a complete therapy that shouldn't be co-administered with other HIV medicines. (merck.com)
Why it matters: For veterinary professionals, this is mainly a market and translational medicine story rather than a clinical one. It shows continued regulatory confidence in streamlined, lower-pill-burden antiviral regimens, and it revives islatravir in a commercial product after earlier development setbacks tied to lymphocyte declines at higher doses. That makes Idvynso notable as both a lifecycle-management move for Merck’s HIV franchise and a reminder that dose optimization can rescue a once-troubled antiviral asset. Phase 3 data cited by Merck showed low rates of virologic rebound in switch studies, helping support the case for a two-drug maintenance option in carefully selected patients. (merck.com)
What to watch: Watch for launch timing, payer access, uptake versus established switch regimens, and whether Merck can extend doravirine/islatravir into broader HIV treatment settings beyond the currently approved switch population. (merck.com)
Merck has won US FDA approval for Idvynso, a once-daily fixed-dose combination of doravirine and islatravir, for adults with HIV-1 who are already virologically suppressed and switching off a stable regimen. The decision, announced April 21, 2026, gives Merck a new single-tablet, two-drug option in a competitive HIV market where simplification, long-term tolerability, and adherence remain central differentiators. (merck.com)
The approval also closes an important chapter in the development of islatravir. Merck had previously faced scrutiny after studies using higher islatravir doses were paused because of declines in total lymphocyte and CD4 counts. The company later reset the program around a lower 0.25 mg dose and continued development in combination with doravirine, ultimately filing an NDA that the FDA accepted in mid-2025 with a PDUFA date of April 28, 2026. The agency acted ahead of that target. (merck.com)
Under the approved label, Idvynso is indicated to replace the current antiretroviral regimen in adults with HIV-1 RNA below 50 copies/mL who have no history of virologic treatment failure and no known substitutions associated with resistance to doravirine. The tablet contains 100 mg of doravirine, a non-nucleoside reverse transcriptase inhibitor, and 0.25 mg of islatravir, which Merck describes as a first-in-class nucleoside reverse transcriptase translocation inhibitor. Merck said the regimen is intended to be used alone, not alongside other HIV medicines. (merck.com)
The clinical package supporting approval centered on switch studies in virologically suppressed adults. In Trial 051, Merck reported that 1% of participants switched to Idvynso had HIV-1 RNA of at least 50 copies/mL at week 48, versus 5% among those who stayed on baseline antiretroviral therapy. Merck also presented 96-week data from the Phase 3 MK-8591A-051 and MK-8591A-052 studies at CROI 2026, alongside data from a separate treatment-naive study, underscoring the company’s broader ambition for the combination beyond the initial switch indication. (merck.com)
Independent commentary was still limited in the first days after approval, but early trade coverage has focused on the product’s role as a new oral simplification option and on the significance of the lower islatravir dose. That framing matters. In HIV, a new approval isn't just about virologic efficacy; it's about whether clinicians trust the durability, safety profile, drug-drug interaction profile, and real-world convenience enough to switch stable patients. The fact that Idvynso enters as a complete, once-daily oral regimen may help it find a place among patients and prescribers who want a simplified oral alternative rather than an injectable approach. This is an inference based on Merck’s positioning and early trade coverage. (merck.com)
Why it matters: For veterinary professionals, this is less about direct practice impact and more about how large animal health and human health companies manage infectious disease portfolios, regulatory risk, and lifecycle strategy. Merck’s handling of islatravir shows how a program can recover after a safety-related reset through dose refinement and narrower initial positioning. That has relevance across biopharma, including companies with both human and animal health footprints, because it highlights how regulators may respond to carefully re-engineered development plans backed by targeted clinical data. (merck.com)
It also reflects a broader industry trend toward treatment simplification where possible. In chronic infectious disease management, reducing regimen complexity can support adherence and persistence, though uptake will depend on comparative comfort versus entrenched standards of care, formulary access, and post-launch safety confidence. For professionals tracking the business side of veterinary medicine, this is another example of how major pharmaceutical companies are trying to defend mature franchises with more tailored, lower-burden therapies. (pharmacytimes.com)
What to watch: The next markers will be commercial availability, coverage decisions, any detailed FDA labeling updates or post-marketing commitments, and whether Merck can convert encouraging broader phase 3 data into additional regulatory filings for treatment-naive adults or other HIV populations. Merck has indicated US pharmacy availability shortly after May 11, 2026, according to trade coverage, but launch execution and clinician confidence will determine whether Idvynso becomes a meaningful switch option or remains a niche product. (grafa.com)